Loading
A phase 1 trial of ISB 2001 in Multiple myeloma, run by Ichnos Sciences SA, now recruiting.
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) is a phase 1 interventional study registered as NCT05862012 by Ichnos Sciences SA, with 200 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-07. Interventions recorded: ISB 2001, ISB 2001. Conditions recorded: Relapsed/Refractory Multiple Myeloma.
Linked to the drug ISB 2001 because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma and the tag pipeline.